TY - JOUR
T1 - Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variants compared with Alpha variant in vaccinated individuals
AU - RIVM COVID-19 molecular epidemiology group
AU - SeqNeth Molecular surveillance group
AU - Andeweg, Stijn P.
AU - Vennema, Harry
AU - Veldhuijzen, Irene
AU - Smorenburg, Naomi
AU - Schmitz, Dennis
AU - Zwagemaker, Florian
AU - Van Gageldonk-Lafeber, Arianne B.
AU - Hahne, Susan J.M.
AU - Reusken, Chantal
AU - Knol, Mirjam J.
AU - Eggink, Dirk
AU - Schinkel, Janke
AU - Welkers, Matthijs R.A.
AU - Jonges, Marcel
AU - Koopsen, Jelle
AU - Jong, Menno D.de
AU - Molenkamp, Richard
AU - Nieuwenhuijse, David F.
AU - Sikkema, Reina S.
AU - Munnink, Bas B.Oude
AU - Koopmans, Marion
AU - van der Zanden, Adri
AU - Manrho, Laura
AU - Beer, Jessica de
AU - Boers, Stefan A.
AU - Meijers, Erin
AU - Vreeswijk, Tom
AU - Sidorov, Igor A.
AU - Dunk, Djoo
AU - Smit, Pieter W.
AU - Pas, Suzan D.
AU - Verweij, Jaco J.
AU - Stohr, Joep J.J.M.
AU - Dingemans, Jozef
AU - Veer, Brian van der
AU - Alphen, Lieke van
AU - Savelkoul, Paul
AU - Niesters, Hubert G.M.
AU - Forero, Erley F.Lizarazo
AU - Fliss, Monika A.
AU - Gard, Lilli
AU - Tanja, Anniek A.N.
AU - Schuurman10, Rob
AU - Wensing, Annemarie M.J.
AU - Hofstra, L. Marije
AU - Coolen, Jordy P.M.
AU - Rahamat-Langendoen1, Janette C.
AU - Melchers, Willem J.G.
AU - Wertheim, Heiman F.L.
AU - Dijkman, Remco
AU - Holstege, Manon M.C.
AU - Vermeulen, Cornelis J.
AU - Schuurman, Sander
AU - van Leeuwen, Karin V.
AU - Keijzer, Nadia
AU - Koets, Lianne
AU - Koppelman, Marco
AU - Aarts, Lynn
AU - Alblas, Jeroen
AU - van Benthem, Birgit V.
AU - Bos, Sanne
AU - Brandt, Annemarie V.D.
AU - van den Brink, Sharon V.D.
AU - Cremer, Jeroen
AU - Faber, Timor
AU - Freriks, Kim
AU - van Gaalen, Rolina
AU - Gier, Brechje de
AU - Geubbels, Eveline
AU - van Heereveld, Janneke
AU - Hajji, Karim
AU - van den Hof, Susan
AU - Hofhuis, Agnetha
AU - van Iersel, Senna
AU - Jaarsma, Ryanne
AU - van de Kassteele, Jan
AU - Kroneman, Annelies
AU - Mulder, Maarten
AU - Lima, Priscila de Oliveira Bressane
AU - Polman, Jan
AU - Schipper, Maarten
AU - Then, Euníce
AU - van der Veer, Bas
AU - Walle, Ivo van
AU - Wijburg, Sara
AU - Wijsman, Lisa
N1 - Publisher Copyright:
© 2023 American Association for the Advancement of Science. All rights reserved.
PY - 2023/2/22
Y1 - 2023/2/22
N2 - The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.
AB - The extent to which severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) break through infection- or vaccine-induced immunity is not well understood. We analyzed 28,578 sequenced SARS-CoV-2 samples from individuals with known immune status obtained through national community testing in the Netherlands from March to August 2021. We found evidence of an increased risk of infection by the Beta (B.1.351), Gamma (P.1), or Delta (B.1.617.2) variants compared with the Alpha (B.1.1.7) variant after vaccination. No clear differences were found between vaccines. However, the effect was larger in the first 14 to 59 days after complete vaccination compared with ≥60 days. In contrast to vaccine-induced immunity, there was no increased risk for reinfection with Beta, Gamma, or Delta variants relative to the Alpha variant in individuals with infection-induced immunity.
UR - https://www.scopus.com/pages/publications/85138518651
U2 - 10.1126/scitranslmed.abn4338
DO - 10.1126/scitranslmed.abn4338
M3 - Article
C2 - 35862508
SN - 1946-6234
VL - 15
JO - Science translational medicine
JF - Science translational medicine
IS - 684
M1 - abn4338
ER -
SDG 3 Good Health and Well-being